HATFIELD, England, November 23, 2015 /PRNewswire/ --
PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/AUSTRIAN/US JOURNALISTS
Key data at the American Epilepsy Society (AES) 69th Annual Meeting in Philadelphia, 4-8 December, will show results from 15 posters on the safety, efficacy, and long-term effects of adjunctive Fycompa(R) (perampanel) in patients with epilepsy.
"These new data at AES 2015 reinforce Eisai's investment in epilepsy treatment options with the potential to improve outcomes in different patient populations. Epilepsy is a challenging condition to manage, it is therefore important that we strive to find effective treatments to support people with epilepsy," comments Neil West, Vice President, Global Neurology Business Unit, Eisai EMEA.
The continued development of its epilepsy portfolio underscores Eisai's human health care (hhc) mission, the company's commitment to innovative solutions in disease prevention, cure and care for the health and wellbeing of people worldwide. Eisai is committed to the therapeutic area of epilepsy and to address the unmet medical needs of people with epilepsy and their families.
The following abstracts are accepted for presentation at the AES annual meeting:
Abstract Number Abstract details
Abstract number: Effect of Adjunctive Perampanel in Pediatric Subjects
#1.184 With Epilepsy: Preliminary Safety and Efficacy Results
Saturday 5 December From Study 232
Hall A, Level 200 Ronald Davis, Jose A. Ferreira, Dinesh Kumar, Haichen
Yang, Antonio Laurenza,Sharon Dispoto
This analysis reports preliminary safety and efficacy
findings from an open-label Phase II pilot study of
perampanel oral suspension in pediatric subjects aged 2
to 4 years. (Rufinamide was originally developed by
- Zonegran(R) (zonisamide) as monotherapy in the treatment of partial seizures, with or
without secondary generalisation, in adults with newly diagnosed epilepsy and as
adjunctive therapy in the treatment of partial seizures, with or without secondary
generalisation, in adults, adolescents and children aged six years and above.
(Zonegran is under license from the originator Dainippon Sumitomo Pharma)
- Zebinix(R) (eslicarbazepine acetate) as adjunctive therapy in adult patients with
partial onset seizures, with or without secondary generalisation (Zebinix is under
license from BIAL)
About Eisai Co., Ltd.
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our hhc philosophy by delivering innovative products in multiple therapeutic areas with high-unmet medical needs, including Oncology and Neurology.
As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit http://www.eisai.com
1. Eisai Data on File, 2015
2. Epilepsy in the WHO European Region: Fostering Epilepsy Care in Europe. http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510.pdf (Accessed November 2015)
3. Pugliatti M et al. Estimating the cost of epilepsy in Europe: A review with economic modeling. Epilepsia 2007:48(12):2224-33
4. Epilepsy Foundation. Types of seizures. Available at: http://www.epilepsy.com/learn/types-seizures. (Accessed November 2015)
5. Epilepsy Foundation. IGE Summary. Available at: http://www.epilepsy.com/information/professionals/about-epilepsy-seizures/idiopathic-generalized-epilepies . (Accessed November 2015)
6. Smithson WH et al, Curr Neurol Neurosci Rep 2014 Dec; 14(12):502
Date of preparation: November 2015
Job code: Fycompa-UK0242
CONTACT: Media Enquiries: Eisai, Cressida Robson/Benjamin Speller,+44(0)7908 314 155/+44(0)845 676 1244, Cressida_Robson@eisai.net ,Ben_Speller@eisai.net ; Tonic Life Communications : Madeleine Nelson/CallumHaire , +44(0)7792473840/+44(0)7725440867 , Madeleine.Nelson@toniclc.com , Callum.Haire@toniclc.com